Given the heterogeneity of RA, the results necessitate expanding the sample size and considering the inclusion of a more diverse patient population, as well as extending the treatment follow‐up period to assess the longitudinal impact on Id2. This evidence concerns the gene ID2 and rheumatoid arthritis.